3 coronavirus stocks I’d buy (and some I’d avoid)

The Covid-19 pandemic is changing society in many ways. Here are three coronavirus stocks I’d buy, and some I’d steer clear of.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The coronavirus pandemic has impacted stocks in wildly differing ways. Of course, with the FTSE All-Share index down over 20% since the start of the year, the impact has been severely negative for many stocks.

However, a perhaps surprising number are showing good gains for the year. This, in spite of – or, in some cases, because of – the Covid-19 pandemic. Here, I want to tell you about three coronavirus stocks I’d buy today, and some I’d avoid.

Big pharma

The world’s big pharma companies are working to develop vaccines for Covid-19. They’re hopeful of success. GlaxoSmithKline CEO Emma Walmsley said yesterday she’s optimistic the industry will be able to make an immunisation against Covid-19. And that it’ll be widely available next year.

In the meantime, we’re making progress on treatments that alleviate the impact of the coronavirus. And more will surely be developed. It seems likely we’ll be in a much better place in 2021 than we’ve been in this year.

Big pharma firms like GlaxoSmithKline could make money from vaccines. But for these multi-billion-pound giants it would be just one of many revenue streams. In other words, Covid-19 isn’t the be-all and end-all for them.

Coronavirus stocks I’d avoid

For small companies, a Covid-19 ‘breakthrough’ could have a big impact. I’ve lost track of the number of UK small-caps that have announced they’re working on some Covid-19-related product or service. Traders and speculators seem to have jumped on such announcements, pushing these companies’ shares up to often crazy valuations.

I’d be inclined to avoid any loss-making small-cap that’s garnered investor interest purely on the back of a tilt at a Covid-19 product or service. I suspect most such companies will fall back into obscurity and their share prices to pre-pandemic levels.

In short, I think investors are on dangerous ground backing profitless small-caps that have made speculative – or in some cases fairly spurious – moves to profit from Covid-19.

Coronavirus stocks I’d buy

I’m much more interested in businesses that should benefit from changes in society that the coronavirus is producing or accelerating. I’m referring to things like online shopping and working from home.

Supermarket giant Tesco boldly doubled its online capacity in the first weeks of the pandemic. This took its market share of UK online grocery sales to 33.5%. Before the pandemic, I’d been impressed by the company’s turnaround and fight-back against discounters like Aldi and Lidl. These bricks-and-mortar discounters now have a lot of ground to make up online, as they acknowledge customer habits are changing. I rate Tesco a ‘buy’.

I’d also happily buy shares of Gamma Communications. It’s a leading supplier of unified communications services to the SME, public sector, and enterprise markets. It enables instant messaging, video calling, multi-party conferencing, and all sorts of other stuff. It’s set to benefit from a likely far larger number of people working from home, or partly from home, than before the pandemic.

Finally, I was keen on gold miners last year, due to the rising level of global debt. Due to the pandemic, money printing and debt have absolutely exploded. In my view, the debasing of paper currencies means we’ll see increasing demand for gold. As such, I think FTSE 100 gold miner Polymetal International is a good stock to buy to benefit from the financial fallout of Covid-19.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Tesco. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£20,000 for a Stocks and Shares ISA? Here’s how to try and turn it into a monthly passive income of £493

Hundreds of pounds in passive income a month from a £20k Stocks and Shares ISA? Here's how that might work…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£5,000 put into Nvidia stock last Christmas is already worth this much!

A year ago, Nvidia stock was already riding high -- but it's gained value since. Our writer explores why and…

Read more »

Investing Articles

Are Tesco shares easy money heading into 2026?

The supermarket industry is known for low margins and intense competition. But analysts are bullish on Tesco shares – and…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Can this airline stock beat the FTSE 100 again in 2026?

After outperforming the FTSE 100 in 2025, International Consolidated Airlines Group has a promising plan to make its business more…

Read more »

Investing Articles

1 Stocks and Shares ISA mistake that will make me a better investor in 2026

All investors make mistakes. The best ones learn from them. That’s Stephen Wright’s plan to maximise returns from his Stocks…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I asked ChatGPT if £20,000 would work harder in an ISA or SIPP in 2026 and it said…

Investors have two tax-efficient ways to build wealth, either in a Stocks and Shares ISA or SIPP. Harvey Jones asked…

Read more »

Investing Articles

How much would I need invested in an ISA to earn £2,417 a month in passive income?

This writer runs the numbers to see what it takes in an ISA to reach £2,417 a month in passive…

Read more »

Investing Articles

Rolls-Royce shares or Melrose Industries: Which one is better value for 2026?

Rolls-Royce shares surged in 2025, surpassing most expectations. Dr James Fox considers whether it offers better value than peer Melrose.

Read more »